Tax-related 721-share sale by Lexeo (LXEO) COO corrected to November 18

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero corrected a prior insider trade report and detailed a small tax-related sale of shares. An earlier Form 4 had mistakenly stated that a sale to cover tax obligations occurred on August 18, 2025. This amendment clarifies that the open-market sale of 721 shares of common stock actually took place on November 18, 2025 at a weighted average price of $9.27 per share, executed in multiple trades between $9.09 and $9.37. The sale was made solely to cover tax obligations from the release of restricted stock units. After this transaction, Otero directly owns 63,476 shares of Lexeo Therapeutics common stock, including 47,733 RSUs, so his overall stake in the company remains largely unchanged.

Insider Trade Summary

Net Seller: 721 shares ($6,684)

Net Sell 1 txn

Insider Otero Jose Manuel

Role Chief Operating Officer

Sold 721 shs ($7K)

Type	Security	Shares	Price	Value
Sale	Common Stock	721	$9.27	$7K

Holdings After Transaction: Common Stock — 63,476 shares (Direct)

Footnotes (1)

1. On November 20, 2025, the reporting person filed a Form 4 which inadvertently reported that a sale to cover tax obligations occurred on August 18, 2025. In fact, as reported in this amendment, the sale occurred on November 18, 2025. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 47,733 RSUs.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Otero Jose Manuel

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/20/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025(1)		S(2)		721	D	$9.27(3)	63,476(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On November 20, 2025, the reporting person filed a Form 4 which inadvertently reported that a sale to cover tax obligations occurred on August 18, 2025. In fact, as reported in this amendment, the sale occurred on November 18, 2025.

2. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

3. This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. Includes 47,733 RSUs.

	/s/ Carole Rosenberg, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lexeo Therapeutics (LXEO) report in this Form 4/A?

Lexeo Therapeutics reported that COO Jose Manuel Otero sold 721 shares of common stock in an open-market transaction. The sale was made solely to cover tax obligations related to the release of restricted stock units, rather than a discretionary portfolio decision.

Why did Lexeo Therapeutics (LXEO) file an amended Form 4/A for Jose Manuel Otero?

The amended Form 4/A corrects the transaction date. A prior filing incorrectly reported that the tax-related sale occurred on August 18, 2025. This amendment clarifies the sale actually occurred on November 18, 2025, updating the record without changing the number of shares sold.

At what price did the Lexeo Therapeutics (LXEO) COO sell shares in the amended Form 4/A?

The COO’s sale of 721 shares was executed at a weighted average price of $9.27 per share. Trades occurred in multiple lots between $9.09 and $9.37, with the reporting person offering to provide full trade details upon request.

How many Lexeo Therapeutics (LXEO) shares does Jose Manuel Otero hold after this transaction?

After the sale, Jose Manuel Otero directly holds 63,476 shares of Lexeo Therapeutics common stock. This amount includes 47,733 restricted stock units (RSUs), indicating that the reported transaction affects only a small portion of his overall equity position.

Was the Lexeo Therapeutics (LXEO) insider sale related to taxes or discretionary selling?

The sale was specifically described as a tax-related transaction. The 721 shares sold were used to cover tax obligations triggered by the release of restricted stock units, rather than representing a discretionary sale aimed at reducing the executive’s ownership stake.

How was the Lexeo Therapeutics (LXEO) insider sale executed according to the Form 4/A?

The transaction was an open-market sale of common stock, executed in multiple trades between $9.09 and $9.37 per share. The weighted average sale price was reported as $9.27, and the reporting person can provide detailed trade breakdowns upon request.